Innovative Medicine
-
New Data from U.S. Post-Approval Study Assess Ischemic Stroke and Intracranial Hemorrhage Rates in People with Non-Valvular Atrial Fibrillation Comparing Both Rivaroxaban with Warfarin and Apixaban with Warfarin
Real-world findings show balance of benefit and risk of XARELTO® (rivaroxaban) with respect to ischemic stroke and a reduction in intracranial hemorrhage in routine clinical practice, further confirming the efficacy and safety profile observed in ROCKET AF -
Real-World Study Further Confirms Safety Profile of XARELTO® in Nearly 45,000 People with Non-Valvular Atrial Fibrillation (NVAF), Including Those with Concomitant Diabetes
Study definitively confirms original results of ROCKET AF and adds to growing body of real-world evidence, informing the safety of XARELTO® in high-risk patients with NVAF -
-
Janssen to Unveil New Hepatitis B and C Data at The International Liver Congress™ 2016 of the European Association for the Study of the Liver (EASL)
Includes several late breaking and oral presentations from across R&D pipeline Highlights potential of R&D pipeline to deliver several new hepatitis B and C regimens -
Real-World Data on XARELTO® in Patients with Non-Valvular Atrial Fibrillation and Diabetes Among 14 Presentations at American College of Cardiology’s 65th Annual Scientific Session
New data add to growing body of real-world evidence supporting physicians and hospitals in optimizing patient care for those at risk of stroke or blood clots -
Real-World Study Found XARELTO® Led to Cost Savings and Shorter Stays in U.S. Hospitals Compared to Warfarin When Used for Treatment of Blood Clots
Findings from this cost savings analysis add to research confirming value of XARELTO® (rivaroxaban) in reducing cost burden to healthcare systems -
First Regimen Combining Long Acting Injectable Antiretrovirals; 32-Week LATTE 2 Study Results Presented at CROI
Intramuscular 2-drug maintenance therapy demonstrates comparable antiviral activity to daily oral 3-drug combination -
Janssen Announces Collaboration with Bavarian Nordic to Develop Vaccine for Chronic Human Papillomavirus (HPV) Infections
New approach for early treatment and interception of HPV-induced cancers -
First Data Unveiled from CALLISTO Program Examining the Use of XARELTO® (rivaroxaban) for Treating Blood Clots in People with Cancer
First of Nine Studies, Examining the Ability of Rivaroxaban to Reduce the Burden of Cancer-Associated Blood Clots, Presented at ASH Annual Meeting